Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its target price decreased by stock analysts at JPMorgan Chase & Co. from $28.00 to $24.00 in a research report issued on Tuesday,Benzinga ...

For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...

Denali Therapeutics (NASDAQ:DNLI – Free Report) had its price objective cut by HC Wainwright from $90.00 to $87.00 in a ...

DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II ...

Denali Therapeutics' DNL343 fails to meet endpoints in the HEALEY ALS study, marking a second clinical setback for the ...

Fintel reports that on January 7, 2025, Baird initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a Outperform ...

In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report), with a price ...

Stock futures were mixed in Tuesday’s premarket session as investors looked ahead to the release of the Job Openings and ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exact Sciences (EXAS – Research Report), Denali ...

Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...